Results 1 to 10 of about 20,235 (182)

HLA‒B*58:01 and skin reactions in pediatric hematology and oncology patients treated with allopurinol [PDF]

Clinical and Experimental Pediatrics
Background Allopurinol is widely used to prevent hyperuricemia in patients with tumor lysis syndrome. However, its use can trigger severe cutaneous adverse reactions (SCARs) with a mortality rate of approximately 11.39%. The human leukocyte antigen (HLA)–
Parisa Maneechai, Cholada Ratanatharathron, Jassada Buaboonam, Kleebsabai Sanpakit   +3 more
doaj   +2 more sources

The anti-inflammatory effect of allopurinol and diclofenac in chicks’ model [PDF]

Iraqi Journal of Veterinary Sciences, 2023
No studies have been conducted on the anti-inflammatory effect of allopurinol; eight-day old chicks are used. The aim of this paper was to study the anti-inflammatory action of allopurinol on a chemical pain model, both when administered alone or in ...
Maab A. Fadel, Khayrea A. Mustafa
doaj   +1 more source

Xanthine oxidase and aldehyde oxidase contribute to allopurinol metabolism in rats

Journal of Pharmaceutical Health Care and Sciences, 2022
Background Allopurinol is used to treat hyperuricemia and gout. It is metabolized to oxypurinol by xanthine oxidase (XO), and aldehyde oxidase (AO). Allopurinol and oxypurinol are potent XO inhibitors that reduce the plasma uric acid levels.
Yoshitaka Tayama, Kazumi Sugihara, Seigo Sanoh, Katsushi Miyake, Shigeyuki Kitamura, Shigeru Ohta   +5 more
doaj   +1 more source

Delayed hypersensitivity reaction to allopurinol: A case report [PDF]

Malaysian Family Physician, 2023
Allopurinol is the well-known first-line treatment option for symptomatic hyperuricaemia and gout. It is cost-effective particularly for the management of chronic gout.
Mohammad Che Man, Shahidah Che Alhadi, Wan Fatimah Suriyani Wan Mahmud, Salman Amiruddin, Mohd Zhafri Mohd Razib, Rasimah Ismail   +5 more
doaj   +1 more source

Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate‐Lowering Response—In Search of a Minimum Effective Oxypurinol Concentration

Clinical and Translational Science, 2020
The aims of this study were to determine factors that predict serum urate (SU) lowering response to allopurinol and the conversion of allopurinol to oxypurinol, and to determine a minimum therapeutic oxypurinol concentration.
Lisa K. Stamp, Peter T. Chapman, Murray Barclay, Anne Horne, Christopher Frampton, Tony R. Merriman, Daniel F. B. Wright, Jill Drake, Nicola Dalbeth   +8 more
doaj   +1 more source

An association study of ABCG2 rs2231142 on the concentrations of allopurinol and its metabolites

Clinical and Translational Science, 2022
ABCG2 is a gene that codes for the human breast cancer resistance protein (BCRP). It is established that rs2231142 G>T, a single nucleotide polymorphism of the ABCG2 gene, is associated with gout and poor response to allopurinol, a uric acid‐lowering ...
Marc‐Olivier Pilon, Grégoire Leclair, Essaïd Oussaïd, Isabelle St‐Jean, Martin Jutras, Marie‐Josée Gaulin, Ian Mongrain, David Busseuil, Jean Lucien Rouleau, Jean‐Claude Tardif, Marie‐Pierre Dubé, Simon deDenus   +11 more
doaj   +1 more source

Impact of Urate Level on Cardiovascular Risk in Allopurinol Treated Patients. A Nested Case-Control Study. [PDF]

PLoS ONE, 2016
BACKGROUND:Gout gives rise to increased risk of cardiovascular events. Gout attacks can be effectively prevented with urate lowering drugs, and allopurinol potentially reduces cardiovascular risk.
Kasper Søltoft Larsen, Anton Pottegård, Hanne M Lindegaard, Jesper Hallas   +3 more
doaj   +1 more source

Allopurinol for Secondary Prevention in Patients with Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Journal of Cardiovascular Development and Disease, 2023
Background: The effects of allopurinol in patients with cardiovascular disease are not well defined; therefore, the latest evidence is summarized in this study. Methods: PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were searched for
Yuyang Ye, Guangzhi Liao, Ting Liu, Xinru Hu, Xuefeng Chen, Lin Bai, Yong Peng   +6 more
doaj   +1 more source

A case series of allopurinol-induced toxic epidermal necrolysis

Indian Journal of Dermatology, 2011
This is a case series of allopurinol-induced toxic epidermal necrolysis. Revisiting the indications of using allopurinol in asymptomatic hyperuricemia and a critical reappraisal of the safety profile of allopurinol is done in this article.
Harneet Ranu, Jackson Jiang, Pang Shiu Ming   +2 more
doaj   +1 more source

PSORS1C1 Hypomethylation Is Associated with Allopurinol-Induced Severe Cutaneous Adverse Reactions during Disease Onset Period: A Multicenter Retrospective Case-Control Clinical Study in Han Chinese

Frontiers in Pharmacology, 2018
Background: Allopurinol-induced severe cutaneous adverse reactions (SCARs), including drug rash with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrosis (TEN), are life-threatening autoimmune reactions.
Bao Sun, Bao Sun, Lin Cheng, Lin Cheng, Yan Xiong, Yan Xiong, Lei Hu, Zhiying Luo, Zhiying Luo, Maosong Zhou, Ji Li, Hongfu Xie, Fazhong He, Fazhong He, Xiaoqing Yuan, Xiaoqing Yuan, Xiaoping Chen, Xiaoping Chen, Hong-Hao Zhou, Hong-Hao Zhou, Zhaoqian Liu, Zhaoqian Liu, Xiang Chen, Xiang Chen, Wei Zhang, Wei Zhang   +25 more
doaj   +1 more source